QuiremSpheres® is based on Holmium-166 microspheres, which were developed in the clinic as an alternative to Yttrium-90 microspheres for treating unresectable liver tumors with selective internal radiation therapy (SIRT). Holmium-166 microspheres can be imaged with SPECT and MR, with high sensitivity and resolution, respectively. This makes it possible to perform post-treatment quantitative verification of the achieved dose distribution, i.e. determining dose-to-tumor and dose-to-tissue. With QuiremSpheres® you treat what you see and see what you treat.
Q-Suite™ allows you to perform accurate post-treatment dosimetry of Holmium-166 SIRT. With Q-Suite™, you can evaluate dose absorption at a voxel level based on SPECT/CT or MR imaging and generate a comprehensive dosimetry report per patient.
166Ho radioembolization is feasible and safe1 for the treatment of patients with unresectable and chemorefractory liver metastases and enables image-guided treatment.
Radioembolization with 166Ho microspheres induced a tumor response with an acceptable toxicity profile in patients with liver metastases.
QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.
QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.
QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.
QuiremSpheres® is not approved in Canada
Our sales representatives are here for you
Radifocus® Guidewire M Non-Vascular
Radifocus® Introducer II Radiopaque Marker Kit C
Radifocus® Guidewire M Shapeable Type
Didn't find your product?